NASDAQ:VRDN

Viridian Therapeutics Stock Forecast, Price & News

$14.46
-0.91 (-5.92 %)
(As of 04/14/2021 04:52 PM ET)
Add
Compare
Today's Range
$14.34
Now: $14.46
$15.66
50-Day Range
$15.50
MA: $17.06
$18.70
52-Week Range
$7.08
Now: $14.46
$25.67
Volume43,252 shs
Average Volume53,649 shs
Market Capitalization$56.51 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Viridian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VRDN
CUSIPN/A
CIKN/A
Phone720 643 5200
Employees45
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$56.51 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

252nd out of 2,019 stocks

Biotechnology Industry

16th out of 145 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$14.46
-0.91 (-5.92 %)
(As of 04/14/2021 04:52 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VRDN News and Ratings via Email

Sign-up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Viridian Therapeutics (NASDAQ:VRDN) Frequently Asked Questions

Is Viridian Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viridian Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Viridian Therapeutics stock.
View analyst ratings for Viridian Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Viridian Therapeutics?

Wall Street analysts have given Viridian Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Viridian Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Viridian Therapeutics?

Viridian Therapeutics saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 94,200 shares, a decrease of 22.1% from the March 15th total of 121,000 shares. Based on an average daily volume of 54,900 shares, the short-interest ratio is currently 1.7 days. Currently, 2.0% of the shares of the stock are sold short.
View Viridian Therapeutics' Short Interest
.

When is Viridian Therapeutics' next earnings date?

Viridian Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Viridian Therapeutics
.

How were Viridian Therapeutics' earnings last quarter?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) posted its quarterly earnings data on Wednesday, March, 24th. The company reported ($5.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.27) by $4.04.
View Viridian Therapeutics' earnings history
.

What price target have analysts set for VRDN?

2 analysts have issued 1 year price objectives for Viridian Therapeutics' shares. Their forecasts range from $28.00 to $40.00. On average, they anticipate Viridian Therapeutics' stock price to reach $34.00 in the next year. This suggests a possible upside of 132.6% from the stock's current price.
View analysts' price targets for Viridian Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Viridian Therapeutics' key executives?

Viridian Therapeutics' management team includes the following people:
  • Mr. Jason A. Leverone CPA, CPA, CFO, Sec. & Treasurer (Age 47, Pay $355k)
  • Dr. William Stuart Marshall Ph.D., Co-Founder & Sr. Technical Advisor (Age 57, Pay $521k)
  • Dr. Jonathan Violin M.B.A., Ph.D., CEO, Pres & Director (Age 46)
  • Dr. Eric N. Olson Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 76)
  • Dr. Marvin H. Caruthers, Co-Founder & Scientific Advisory Board Member (Age 81)
  • Mr. Vahe Bedian Ph.D., Chief Scientist
  • Ms. Lee M. Rauch, Consultant (Age 66)
  • Dr. Barrett Katz M.B.A., M.D., MBA, CMO, Chief Medical Officer
  • Dr. Aimee L. Jackson, VP of Research

Who are some of Viridian Therapeutics' key competitors?

What is Viridian Therapeutics' stock symbol?

Viridian Therapeutics trades on the NASDAQ under the ticker symbol "VRDN."

How do I buy shares of Viridian Therapeutics?

Shares of VRDN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viridian Therapeutics' stock price today?

One share of VRDN stock can currently be purchased for approximately $14.62.

How much money does Viridian Therapeutics make?

Viridian Therapeutics has a market capitalization of $57.13 million.

How many employees does Viridian Therapeutics have?

Viridian Therapeutics employs 45 workers across the globe.

What is Viridian Therapeutics' official website?

The official website for Viridian Therapeutics is www.viridiantherapeutics.com.

How can I contact Viridian Therapeutics?

The company can be reached via phone at 720 643 5200.


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.